Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07231757 · ClinicalTrials.gov registry record

The RADIANCE CED Study

A clinical trial of Hypertension and Cardiovascular Diseases, sponsored by ReCor Medical.

Recruiting
Registry status
1,000
Enrollment target
1
Study location

NCT07231757 is a study of Hypertension and Cardiovascular Diseases that is actively recruiting participants, run by ReCor Medical. The registered enrollment target is 1,000 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07231757, a study of Hypertension and Cardiovascular Diseases, is actively recruiting participants, sponsored by ReCor Medical.

RECRUITING
Registry status
1,000 participants
Enrollment target
1
Study location

Study Summary

The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible patients to support generalizability of outcomes to the broader Medicare population. Individual hospital enrollment is not required for this study and IRB exemption has been received by sponsor.

Interventions

  • DEVICE Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)

Study Locations (1)

Michigan

  • Henry Ford St. John Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2025-11-21
Est. Completion 2031-12-31

Sponsor

ReCor Medical

5 total trials

What the Registry Record Tells You About NCT07231757

The ClinicalTrials.gov registry entry for NCT07231757 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The listed sponsor is ReCor Medical, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System) is the first listed.

NCT07231757 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT07231757 about?

NCT07231757 is a clinical study titled "The RADIANCE CED Study". The RADIANCE CED study is a prospective observational study designed to evaluate the long-term effectiveness of ultrasound renal denervation in lowering blood pressure among patients with uncontrolled hypertension. Data will be collected from electronic health records (EHRs) of Medicare-eligible pat...

What is the current status of trial NCT07231757?

This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2025-11-21. Estimated completion is 2031-12-31.

What conditions does trial NCT07231757 study?

This clinical trial studies the following conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases.

What interventions are being tested in trial NCT07231757?

The interventions under investigation include: Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System) (DEVICE).

Who is sponsoring clinical trial NCT07231757?

This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07231757 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.